Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cannabis Wheaton Income Corp. stock logo
CBWTF
Cannabis Wheaton Income
$0.10
-8.0%
$0.07
$0.02
$0.13
$138.34M1.041.53 million shs1.01 million shs
National Research Corporation stock logo
NRC
National Research
$15.96
-1.9%
$15.11
$9.76
$27.07
$370.83M0.4589,425 shs47,793 shs
Starpharma Holdings Ltd. stock logo
SPHRY
Starpharma
$0.63
$0.58
$0.47
$0.80
$26.22M0.76167 shsN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
+84.6%
$0.00
$0.00
$0.02
$1.32M0.9892,222 shs78,192 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cannabis Wheaton Income Corp. stock logo
CBWTF
Cannabis Wheaton Income
-8.01%+4.04%+57.26%+64.03%+331.22%
National Research Corporation stock logo
NRC
National Research
-1.91%-6.28%-0.68%+49.16%-28.75%
Starpharma Holdings Ltd. stock logo
SPHRY
Starpharma
-0.01%-1.90%+2.97%+6.26%+4.49%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
+84.62%+84.62%+14.29%+140.00%-78.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cannabis Wheaton Income Corp. stock logo
CBWTF
Cannabis Wheaton Income
0.3664 of 5 stars
0.03.00.00.00.60.01.3
National Research Corporation stock logo
NRC
National Research
2.4387 of 5 stars
0.04.01.70.01.92.51.3
Starpharma Holdings Ltd. stock logo
SPHRY
Starpharma
N/AN/AN/AN/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.3766 of 5 stars
0.01.00.04.30.00.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cannabis Wheaton Income Corp. stock logo
CBWTF
Cannabis Wheaton Income
0.00
N/AN/AN/A
National Research Corporation stock logo
NRC
National Research
0.00
N/AN/AN/A
Starpharma Holdings Ltd. stock logo
SPHRY
Starpharma
0.00
N/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cannabis Wheaton Income Corp. stock logo
CBWTF
Cannabis Wheaton Income
$89.29M1.43N/AN/A$0.06 per share1.59
National Research Corporation stock logo
NRC
National Research
$143.06M2.54$1.31 per share12.19$1.36 per share11.74
Starpharma Holdings Ltd. stock logo
SPHRY
Starpharma
$6.40M4.10N/AN/A$0.45 per share1.39
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.02N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cannabis Wheaton Income Corp. stock logo
CBWTF
Cannabis Wheaton Income
-$11.93M$0.019.54N/A16.56%18.53%8.13%N/A
National Research Corporation stock logo
NRC
National Research
$24.78M$1.0315.50N/A17.14%71.33%18.67%7/28/2025 (Estimated)
Starpharma Holdings Ltd. stock logo
SPHRY
Starpharma
-$5.36MN/A0.00N/AN/AN/AN/A8/20/2025 (Estimated)
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84MN/A0.00N/AN/AN/AN/AN/A

Latest SRNE, CBWTF, NRC, and SPHRY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Cannabis Wheaton Income Corp. stock logo
CBWTF
Cannabis Wheaton Income
N/A$0.01N/A$0.01N/AN/A
4/28/2025Q1 2025
National Research Corporation stock logo
NRC
National Research
N/A$0.25N/A$0.25N/A$33.55 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cannabis Wheaton Income Corp. stock logo
CBWTF
Cannabis Wheaton Income
N/AN/AN/AN/AN/A
National Research Corporation stock logo
NRC
National Research
$0.483.01%N/A46.60%N/A
Starpharma Holdings Ltd. stock logo
SPHRY
Starpharma
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A

Latest SRNE, CBWTF, NRC, and SPHRY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/25/2025
National Research Corporation stock logo
NRC
National Research
quarterly$0.124.1%6/27/20256/27/20257/11/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cannabis Wheaton Income Corp. stock logo
CBWTF
Cannabis Wheaton Income
0.02
0.68
0.34
National Research Corporation stock logo
NRC
National Research
1.98
0.54
0.54
Starpharma Holdings Ltd. stock logo
SPHRY
Starpharma
N/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Cannabis Wheaton Income Corp. stock logo
CBWTF
Cannabis Wheaton Income
N/A
National Research Corporation stock logo
NRC
National Research
47.26%
Starpharma Holdings Ltd. stock logo
SPHRY
Starpharma
N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%

Insider Ownership

CompanyInsider Ownership
Cannabis Wheaton Income Corp. stock logo
CBWTF
Cannabis Wheaton Income
4.60%
National Research Corporation stock logo
NRC
National Research
8.10%
Starpharma Holdings Ltd. stock logo
SPHRY
Starpharma
N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cannabis Wheaton Income Corp. stock logo
CBWTF
Cannabis Wheaton Income
3691.34 billion1.26 billionNot Optionable
National Research Corporation stock logo
NRC
National Research
49022.78 million20.94 millionOptionable
Starpharma Holdings Ltd. stock logo
SPHRY
Starpharma
4541.82 millionN/ANot Optionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
800551.28 million536.95 millionNo Data

Recent News About These Companies

Sorrento Therapeutics Inc (SRNE) - Investing.com
SRNE Sorrento Therapeutics, Inc. - Seeking Alpha
Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
Sorrento Therapeutics Inc (SRNE)
Sorrento Therapeutics Inc SRNE
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)
Sorrento Therapeutics
5 Sanders Cove, Sorrento WA 6020

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cannabis Wheaton Income stock logo

Cannabis Wheaton Income OTCMKTS:CBWTF

$0.10 -0.01 (-8.01%)
As of 07/11/2025 03:58 PM Eastern

Auxly Cannabis Group Inc. operates as a consumer packaged goods company in the cannabis products market in Canada. It focuses on developing, manufacturing, and distributing cannabis products for wellness and recreational consumers. The company offers cannabis products under various forms, including vape catridges, infused pre-rolls, pre-rolled, vape pens, milled and dried flower, concentrates, chocolates, soft chews, oil drops, capsules, and topicals under the KOLAB PROJECT, Dosecann, BACK FORTY, Foray, and Parcel brand names. It sells its products through supply arrangements with provincial control boards and distributors, medical cannabis sales channels, and retailers, as well as to authorized wholesalers. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. The company was incorporated in 1987 and is headquartered in Toronto, Canada.

National Research stock logo

National Research NASDAQ:NRC

$15.96 -0.31 (-1.91%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$15.99 +0.03 (+0.19%)
As of 07/11/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.

Starpharma stock logo

Starpharma OTCMKTS:SPHRY

$0.63 0.00 (0.00%)
As of 07/11/2025

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0024 +0.00 (+84.62%)
As of 07/11/2025 03:46 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.